China Collaborative Study on Epidemiology of Acute Kidney Injury

December 10, 2022 updated by: XinLing Liang
Acute kidney injury (AKI) is a common clinical syndrome, especially patients in the hospital. AKI has become a huge medical burden in China. Little information is available about this disease burden in our country. The investigators aimed to evaluate the burden of AKI and to analyze the related risk factors.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The investigators launch a nationwide of all patients, who were admitted to hospital from 2011-2016. Patients were diagnosed on the basis of changes in serum creatinine by the laboratory information system. The investigators assessed rates of AKI according to the criteria of 2012 Kidney Disease Improving Global Outcomes (KDIGO).

Study Type

Observational

Enrollment (Anticipated)

1000000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • China
    • Guangdong
      • Guangzhou, Guangdong, China
        • Recruiting
        • Nephrology Dept,Guangdong General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

All inpatients (if outpatient identification is achieved, outpatient and inpatient patients can be judged to be the same individual, the outpatient electronic data is extracted at the same time)

Description

Inclusion Criteria:

  • The patients diagnosed on the basis of changes in serum creatinine according to the criteria of 2012 Kidney Disease Improving Global Outcomes(KDIGO)

Exclusion Criteria:

  • Serum creatinine record less than two times during hospitalization
  • Patients being diagnosed with End-stage kidney disease (chronic kidney disease stage 5)
  • Nephrectomy
  • Kidney transplantation
  • Peak serum creatinine of less than 53µ mol/L
  • Serum creatinine decrease after amputation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
AKI
Other: no intervention
non-AKI
Other: no intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Incidence of AKI
Time Frame: Jan. 2011 to Oct. 2016
Jan. 2011 to Oct. 2016

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Recognition rate of AKI
Time Frame: Jan. 2011 to Oct. 2016
Using machine learning and deep learning methods to establish AKI prediction model and risk models
Jan. 2011 to Oct. 2016
Proportion of nephrology referral
Time Frame: Jan. 2011 to Oct. 2016
Jan. 2011 to Oct. 2016
In-hospital mortality
Time Frame: Jan. 2011 to Oct. 2016
Jan. 2011 to Oct. 2016
Longer ICU stay
Time Frame: Jan. 2011 to Oct. 2016
Jan. 2011 to Oct. 2016
Higher medical cost
Time Frame: Jan. 2011 to Oct. 2016
Jan. 2011 to Oct. 2016

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

XinLing Liang

Investigators

  • Principal Investigator: Liang Xinling, M.D.,Ph.D, Nephrology Dept,Guangdong General Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2017

Primary Completion (Anticipated)

December 31, 2027

Study Completion (Anticipated)

December 31, 2027

Study Registration Dates

First Submitted

February 13, 2017

First Submitted That Met QC Criteria

February 14, 2017

First Posted (Actual)

February 15, 2017

Study Record Updates

Last Update Posted (Estimate)

December 13, 2022

Last Update Submitted That Met QC Criteria

December 10, 2022

Last Verified

December 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CCS-AKI RF2011-2016

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Kidney Injury

Clinical Trials on no intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe